English
English
Chinese (Simplified)
NASDAQ: INMB
SIGN UP
What’s New
About
Back
Corporate Overview
Management
Directors
Therapies
Back
Pipeline
INKmune™ – Cancer
Back
Overview
Clinical trials
Publications
Videos
INB03 – Cancer
Back
Overview
Clinical trials
Publications
Videos
XPro1595 – Alzheimer's
Back
Overview
Clinical trials
Publications
Videos
XPRO1595 – TRD
Back
Overview
Videos
LIVNate ™
Back
Overview
Publications
Quellor™
Back
Overview
Publications
Investors
Back
Corporate Governance
IR Events
Presentation
Filings
Stock Quote
Analyst Coverage
News and Media
Back
2021
2020
2019
2018
2017
Media Coverage
Contact
Back
Contact Us
Subscribe for Updates
2021 News
Title Filter
All
Corporate
General
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
21 Jan, 2021
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET
13 Jan, 2021
Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST
English
Chinese (Simplified)